4:38 PM
 | 
Aug 16, 2013
 |  BC Extra  |  Clinical News

Prosensa slides on analyst note on DMD data

Prosensa Holding N.V. (NASDAQ:RNA) slipped $2.29 to $26.25 on Friday after an analyst said newly released data suggest a "substantial number" of Duchenne muscular dystrophy (DMD) patients "may not be getting a meaningful drug effect" with Prosensa's drisapersen...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >